中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址(location):北京市丰台区丽泽路 20 号丽泽 SOHO B 座 20 层 20/F,Tower B,Lize SOHO,20 Lize Road,Fengtai District,Beijing PR China (tel):010-51423818 传真(fax):010-51423816 审计报告 中兴华审字(2025)第 020779 号 南京麦澜德医疗科技股份有限公司全体股东: 一、审计意见 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册 会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。按照 中国注册会计师职业道德守则,我们独立于麦澜德公司,并履行了职业道德方面的 其他责任。我们相信,我们获取的审计证据是充分、适当的,为发表审计意见提供 了基础。 三、关键审计事项 关键审计事项是根据我们的职业判断,认为对本期财务报表审计最为重要的事 项。这些事项的应对以对财务报表整体进行审计并形成审计意见为背景,我们不对 这些事项单独发 ...

中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS ILb 地址(location): 北京市丰台区丽泽路 20 号丽泽 S0H0 B 座 20 层 Tower B,Lize SOHO,20 Lize Road,Fengtai District,Beijing PR China 电话(tel):010-51423818 传真(fax):010-51423816 内部控制审计报告 中兴华内控审计字(2025)第 020033 号 南京麦澜德医疗科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我们 审计了南京麦澜德医疗科技股份有限公司(以下简称"麦澜德公司")2024年 12 月 31 日的财务报告内部控制的有效性。 一、麦澜德公司对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制评 价指引》的规定,建立健全和有效实施内部控制,并评价其有效性是麦澜德公司董 事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上,对财务报告内部控制的有效性发表审 计意 ...

南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 2024 年度募集资金存放与实际使用情况的专项核查意见 南京证券股份有限公司（以下简称"南京证券"或"保荐机构"）作为南京 麦澜德医疗科技股份有限公司（以下简称"麦澜德"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管 指引第 1 号——规范运作》《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求》等有关规定，对麦澜德 2024 年度募集资金存放与实际使用 情况进行了认真、审慎地核查，核查情况如下： 一、募集资金的基本情况 （一）实际募集资金金额、资金到账时间 根据中国证券监督管理委员会出具的《关于同意南京麦澜德医疗科技股份有 限公司首次公开发行股票注册的批复》（证监许可〔2022〕1189 号），公司首次 向社会公开发行人民币普通股 2,500 万股，每股发行价格为人民币 40.29 元，募集 资金总额为 1,007,250,000.00 元；减除发行费用 97,491,500.00 元（不含税）后，募 集资金净 ...

南京证券股份有限公司 关于南京麦澜德医疗科技股份有限公司 使用暂时闲置自有资金购买理财产品的核查意见 南京证券股份有限公司（以下简称"南京证券"或"保荐机构"）作为南京 麦澜德医疗科技股份有限公司（以下简称"麦澜德"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管 指引第 1 号——规范运作》等有关规定，对麦澜德使用暂时闲置自有资金购买理 财产品的事项进行了认真、审慎的核查，核查情况如下： 一、使用闲置自有资金购买理财产品的概况 （一）投资目的 在不影响公司正常生产经营、充分保障公司开支需求并有效控制风险的前提 下，公司使用暂时闲置自有资金购买风险较低、安全性高、流动性好的理财产品， 有利于提高资金使用效益，增强公司短期现金的管理能力，获得更好的财务收益， 为公司及股东获取更多回报。 （二）投资品种 公司将按照相关规定严格控制风险，对投资产品进行严格评估，将自有资金 投向风险较低、安全性高、流动性好的理财产品，投资产品不得用于质押，不得 用于以证券投资为目的的投资行为。 （三）投资产品的额度 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥118,279,190.58, representing a 13.36% increase compared to ¥104,336,800.77 in the same period last year[4] - Net profit attributable to shareholders was ¥39,859,710.56, up 9.85% from ¥36,286,016.09 year-over-year[4] - The net profit after deducting non-recurring gains and losses was ¥37,582,005.84, reflecting an 11.60% increase from ¥33,674,390.42 in the previous year[4] - Total operating revenue for Q1 2025 reached ¥118,279,190.58, an increase of 13.5% compared to ¥104,336,800.77 in Q1 2024[18] - Operating costs for Q1 2025 were ¥79,132,614.70, up from ¥67,441,073.51 in Q1 2024, reflecting a 17.4% increase[19] - Net profit for Q1 2025 was ¥39,283,674.65, compared to ¥38,187,419.68 in Q1 2024, representing a growth of 2.9%[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.4073, an increase from ¥0.3660 in Q1 2024[20] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥662,603.27, a significant decrease of 116.33% compared to a net inflow of ¥4,058,727.37 in the same period last year[4] - Cash flow from operating activities in Q1 2025 was ¥102,616,856.12, compared to ¥89,637,302.03 in Q1 2024, indicating a growth of 14.9%[21] - Net cash flow from operating activities decreased to -$662,603.27 from $4,058,727.37 year-over-year[22] - The company reported a total cash inflow from operating activities of $107,767,124.57, compared to $96,522,539.04 previously[22] - Total cash outflow from operating activities increased to $108,429,727.84 from $92,463,811.67[22] Research and Development - Research and development expenses totaled ¥15,004,116.64, which is a 15.87% increase from ¥12,949,133.49 in the previous year[4] - The proportion of R&D expenses to operating revenue increased to 12.69%, up 0.28 percentage points from 12.41% year-over-year[5] - Research and development expenses for Q1 2025 were ¥14,479,582.13, up from ¥12,949,133.49 in Q1 2024, reflecting an increase of 11.8%[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,524,160,130.51, a decrease of 1.45% from ¥1,546,621,500.61 at the end of the previous year[5] - Total liabilities decreased to ¥139,219,395.83 from ¥199,662,048.19, showing a reduction of 30.3%[16] - Total current assets decreased to RMB 953,390,381.27 from RMB 1,001,656,821.36, indicating a decline of approximately 4.8%[14] - The company's accounts receivable increased to RMB 23,805,181.67 from RMB 15,179,617.47, representing a growth of about 56.8%[14] - The inventory decreased to RMB 67,359,597.90 from RMB 73,049,282.47, reflecting a decline of approximately 7.3%[14] - The company's long-term equity investments were valued at RMB 19,725,632.10, a slight decrease from RMB 20,472,265.48[14] - The total non-current assets remained relatively stable, with a slight increase in construction in progress to RMB 229,194,763.36 from RMB 203,001,882.28[14] - The company's goodwill remained unchanged at RMB 41,899,723.22, indicating stability in this asset category[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 4,927[8] - The top two shareholders, Yang Ruijia and Shi Zhihuai, held 19.36% and 18.15% of the shares, respectively[9] - The repurchase account held 2,190,943 shares, representing 2.19% of total shares as of March 31, 2025[12] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[11] - There were no significant changes in the participation of major shareholders in margin trading or securities lending activities[11]

Financial Performance - The company achieved a net profit attributable to shareholders of 101,581,195.08 CNY for the fiscal year 2024[7]. - The proposed cash dividend is 4.00 CNY per 10 shares, totaling 39,123,142.80 CNY to be distributed among 97,807,857 shares[7]. - As of December 31, 2024, the company's distributable profits amounted to 158,884,120.13 CNY[7]. - The total share capital of the company is 100,000,000 shares, with 2,192,143 shares in the repurchase account excluded from dividends[7]. - The company does not plan to increase capital through reserves or issue bonus shares[7]. - The company's operating revenue for 2024 reached ¥424,549,436.34, representing a 24.57% increase compared to ¥340,824,682.52 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥101,581,195.08, up 13.10% from ¥89,817,910.06 in 2023[23]. - The net profit after deducting non-recurring gains and losses was ¥82,002,994.57, reflecting a 14.63% increase from ¥71,537,863.76 in 2023[23]. - The company's total assets as of the end of 2024 were ¥1,546,621,500.61, a 0.83% increase from ¥1,533,923,915.26 at the end of 2023[23]. - Basic earnings per share for 2024 were ¥1.0309, which is a 14.77% increase compared to ¥0.8982 in 2023[24]. - The net cash flow from operating activities for 2024 was ¥122,508,138.42, a decrease of 10.52% from ¥136,908,370.75 in 2023[23]. - The company reported a quarterly revenue of ¥104,336,800.77 in Q1 2024, with net profit attributable to shareholders of ¥36,286,016.09[26]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, aiming for a 10% market share by the end of 2025[13]. - A strategic acquisition of a competitor is in progress, which is expected to enhance the company's product portfolio and increase market competitiveness[13]. - The company is actively involved in key national and provincial research projects, including AI-assisted pelvic floor rehabilitation technology[34]. - The company is expanding its international market presence by developing an international version of the PI-ONE system[37]. - The company is focusing on integrating AI technology into its diagnostic processes, aiming to enhance decision-making efficiency and accuracy in treatment plans[44]. - The company is committed to enhancing its product matrix by leveraging optical imaging, focused ultrasound, and AI technologies to improve diagnostic capabilities[40]. - The company aims to enhance women's health and beauty sectors, focusing on reproductive rehabilitation and anti-aging technologies[65]. - The company is focusing on expanding its product offerings in pelvic floor rehabilitation equipment and services[166]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million allocated for potential deals[199]. Research and Development - The company is investing RMB 50 million in R&D for innovative technologies in medical devices[13]. - The R&D investment as a percentage of operating revenue decreased to 14.67% in 2024 from 17.09% in 2023, a reduction of 2.42 percentage points[24]. - The company has established an independent R&D center with various specialized departments to continuously optimize product performance through technological upgrades[53]. - The company has developed a pelvic floor rehabilitation electrophysiology technology platform, enabling personalized treatment for various pelvic floor disorders[71]. - The company has developed the world's first intelligent pelvic floor diagnosis and treatment system, PI-ONE, which utilizes AI algorithms for intelligent analysis of assessment data[185]. - The company is focusing on personalized treatment plans through AI and big data analysis to maintain industry competitiveness[93]. - The company has developed a unique multimodal motion closed-loop control system that provides individualized treatment plans based on real-time recovery status, enhancing rehabilitation outcomes[109]. - The company has initiated significant research projects, including a key technology development project for a medical ultrasound multimodal foundational model, expected to run from 2024 to 2027[85]. Product Development and Innovation - New product development includes a cutting-edge medical device expected to launch in Q3 2024, projected to generate RMB 200 million in sales[13]. - The company launched the PI-ONE system, an AI-assisted solution for pelvic floor rehabilitation, enhancing assessment and treatment capabilities[35]. - The company is developing next-generation vaginal electrodes tailored to women's anatomy, enhancing treatment effectiveness[72]. - The company has developed a new generation of pelvic floor ultrasound intelligent diagnostic systems, with a total expected investment of ¥40,520,000[90]. - The company has developed a multi-channel high-frequency ultrasound technology platform, capable of producing up to 16 channels of focused ultrasound output, significantly enhancing clinical application options[76]. - The company has introduced a uterine restoration device in the field of obstetrics and gynecology, featuring automated control with three motion trajectories and nine speed adjustment levels, improving clinical efficiency[76]. - The company is developing next-generation laser products, including picosecond dual-wavelength laser devices, to enhance its optical and laser product line[81]. - The company has launched the 3D Skin Analyzer P2 (Professional Version) and AI Morphology Analyzer, enhancing user experience by reducing AI analysis time[96]. Governance and Compliance - The board of directors and supervisory board members have confirmed the accuracy and completeness of the annual report[3]. - The company has established a system for independent directors to enhance decision-making fairness and scientificity[192]. - The company’s governance structure is compliant with the regulations set by the China Securities Regulatory Commission, ensuring operational independence[193]. - The company held 5 shareholder meetings, 8 board meetings, and 7 supervisory meetings during the reporting period, ensuring robust governance practices[192]. - The independent directors and supervisors have maintained their shareholdings at 8 shares each throughout the reporting period[197]. Market Trends and Industry Insights - The overall revenue of China's medical device industry reached CNY 1.31 trillion in 2023, with an average annual growth rate of 10% from 2014 to 2023, indicating a robust market[56]. - The rehabilitation medical device market in China is projected to reach CNY 94.15 billion by 2026, driven by an aging population and increasing chronic disease prevalence[58]. - The prevalence of pelvic floor dysfunction (PFD) among women in China is increasing, with a reported incidence rate of 65.24% among women aged 53.61 years in Beijing in 2018[60]. - The infertility rate in China is projected to rise from 12.5%-15% in 2016 to 18% by 2025, translating to approximately 60 million patients[61]. - The annual number of abortions in China reached 9.76 million in 2019, indicating a significant impact on women's reproductive health and fertility[61]. - The market for light medical aesthetics in China is projected to reach approximately 415.7 billion RMB by 2030, indicating significant growth potential[61]. - The clinical demand for reproductive rehabilitation is rapidly increasing, with infertility rates rising from 11.9% in 2007-2010 to nearly 18% in 2020, affecting approximately 50.5 million couples in China[174]. Operational Efficiency and Cost Management - The company is actively monitoring raw material price fluctuations to optimize procurement strategies and maintain cost efficiency[121]. - The company achieved operating revenue of CNY 424.55 million in 2024, a 24.57% increase from CNY 340.82 million in the same period last year[125]. - The main business revenue increased by 30.40% to CNY 418.41 million, with main business costs rising by 42.76% to CNY 116.13 million, resulting in a decrease in gross margin by 2.40 percentage points[127]. - Operating expenses have been reduced by 5% due to efficiency improvements in the supply chain[199]. - The intelligent cost control management platform will integrate budget control and risk warning functions to achieve refined cost management[190].

南京麦澜德医疗科技股份有限公司 2024 年度独立董事述职报告 本人作为南京麦澜德医疗科技股份有限公司（以下简称"公司"）的独立董 事，严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司 治理准则》《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》 等有关法律、法规、规范性文件以及《南京麦澜德医疗科技股份有限公司章程》 （以下简称"《公司章程》"）和《南京麦澜德医疗科技股份有限公司独立董事 工作制度》（以下简称"《独立董事工作制度》"）的规定和要求，认真、勤勉、 独立的履行职责，积极出席相关会议，认真审议董事会各项议案，充分发挥了独 立董事及各专门委员会委员的作用，切实维护了公司和全体股东的利益。现本人 将 2024 年度的工作情况汇报如下： 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 冷德嵘先生，1963 年 10 月出生，中国国籍，无境外永久居留权，本科学历， 研高级工程师。冷德嵘先生于 1985 年 7 月参加工作，曾先后任职于昆明手扶拖 拉机厂、江苏周林频谱公司；1999 年联合创办南京微创医疗产品有限公司；2000 年 5 月至 2015 年 7 ...

南京麦澜德医疗科技股份有限公司 2024 年度独立董事述职报告 本人作为南京麦澜德医疗科技股份有限公司（以下简称"公司"）的独立董 事，严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司 治理准则》《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》 等有关法律、法规、规范性文件以及《南京麦澜德医疗科技股份有限公司章程》 （以下简称"《公司章程》"）和《南京麦澜德医疗科技股份有限公司独立董事 工作制度》（以下简称"《独立董事工作制度》"）的规定和要求，认真、勤勉、 独立的履行职责，积极出席相关会议，认真审议董事会各项议案，充分发挥了独 立董事及各专门委员会委员的作用，切实维护了公司和全体股东的利益。现本人 将 2024 年度的工作情况汇报如下： 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 舒柏晛先生，1982 年 6 月出生，中国国籍，无境外永久居留权，硕士研究 生学历，保荐代表人。2007 年 7 月至 2014 年 9 月先后就职于华泰证券股份有限 公司、中航证券有限公司；2014 年 9 月至 2023 年 3 月任国金证券股份有限公司 职员、国金证券上 ...

南京麦澜德医疗科技股份有限公司 章 程 二〇二五年四月 | | | | 第一章 | 总则 | 4 | | --- | --- | --- | | 第二章 | 经营宗旨和经营范围 5 | | | 第三章 | 股份 | 6 | | 第一节 | 股份发行 | 6 | | 第二节 | 股份增减和回购 | 7 | | 第三节 | 股份转让 | 9 | | 第四章 | 股东和股东大会 9 | | | 第一节 | 股东 | 9 | | 第二节 | 股东大会的一般规定 12 | | | 第三节 | 股东大会的召集 | 17 | | 第四节 | 股东大会的提案与通知 18 | | | 第五节 | 股东大会的召开 | 20 | | 第六节 | 股东大会的表决和决议 23 | | | 第五章 | 董事会 | 28 | | 第一节 | 董事 | 28 | | 第二节 | 独立董事 | 31 | | 第三节 | 董事会 | 37 | | 第四节 | 董事会专门委员会 42 | | | 第六章 | 总经理及其他高级管理人员 43 | | | 第七章 | 监事会 | 46 | | 第一节 | 监事 | 46 | | 第二节 | 监事会 | ...

南京麦澜德医疗科技股份有限公司 2024 年度独立董事述职报告 本人作为南京麦澜德医疗科技股份有限公司（以下简称"公司"）的独立董 事，严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司 治理准则》《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》 等有关法律、法规、规范性文件以及《南京麦澜德医疗科技股份有限公司章程》 （以下简称"《公司章程》"）和《南京麦澜德医疗科技股份有限公司独立董事 工作制度》（以下简称"《独立董事工作制度》"）的规定和要求，认真、勤勉、 独立的履行职责，积极出席相关会议，认真审议董事会各项议案，充分发挥了独 立董事及各专门委员会委员的作用，切实维护了公司和全体股东的利益。现本人 将 2024 年度的工作情况汇报如下： 一、独立董事基本情况 （一）个人工作履历、专业背景以及兼职情况 | 审计委员会 | | 薪酬与考核委员会 | | | --- | --- | --- | --- | | 应出席数 | 实际出席数 | 应出席数 | 实际出席数 | | 6 | 6 | 2 | 2 | 袁天荣女士，1964 年 6 月生，中国国籍，无境外永久居留权，博士研究生 ...